Neuroimaging of Diseases Causing Dementia

Joseph C. Masdeu

doi:10.1016/j.ncl.2019.08.003

Neuroimaging of Diseases Causing Dementia

Joseph C. Masdeu

Research output: Contribution to journal › Review article › peer-review

8 Scopus citations

Abstract

Neuroimaging provides a window on the biological events underlying dementia. Amyloid PET is positive in Alzheimer disease (AD) and some cases of diffuse Lewy body disease, but negative in the frontotemporal dementias (FTDs). Tau PET using the current tracers shows the greatest signal in AD and a lesser signal in FTD. Quantifying volume loss with MRI and measuring metabolism with fluorodeoxyglucose PET helps separate different causes of dementia and follow their progression. Brain inflammation can be assessed with PET. Some of these techniques, still investigational, are likely to find their clinical niche in the near future.

Original language	English (US)
Pages (from-to)	65-94
Number of pages	30
Journal	Neurologic Clinics
Volume	38
Issue number	1
DOIs	https://doi.org/10.1016/j.ncl.2019.08.003
State	Published - Feb 2020

Keywords

Alzheimer disease
Amyloid β
Neurodegeneration
Neuroimaging
PET
Tau
tau Proteins/metabolism
Humans
Magnetic Resonance Imaging/methods
Disease Progression
Dementia/diagnostic imaging
Neuroimaging/methods
Frontotemporal Dementia/diagnostic imaging
Alzheimer Disease/diagnostic imaging
Positron-Emission Tomography/methods
Lewy Body Disease/diagnostic imaging

ASJC Scopus subject areas

Clinical Neurology

Access to Document

10.1016/j.ncl.2019.08.003

Cite this

@article{e6a0d5f9944047b38933c6d01c7b0a8e,

title = "Neuroimaging of Diseases Causing Dementia",

abstract = "Neuroimaging provides a window on the biological events underlying dementia. Amyloid PET is positive in Alzheimer disease (AD) and some cases of diffuse Lewy body disease, but negative in the frontotemporal dementias (FTDs). Tau PET using the current tracers shows the greatest signal in AD and a lesser signal in FTD. Quantifying volume loss with MRI and measuring metabolism with fluorodeoxyglucose PET helps separate different causes of dementia and follow their progression. Brain inflammation can be assessed with PET. Some of these techniques, still investigational, are likely to find their clinical niche in the near future.",

keywords = "Alzheimer disease, Amyloid β, Neurodegeneration, Neuroimaging, PET, Tau, tau Proteins/metabolism, Humans, Magnetic Resonance Imaging/methods, Disease Progression, Dementia/diagnostic imaging, Neuroimaging/methods, Frontotemporal Dementia/diagnostic imaging, Alzheimer Disease/diagnostic imaging, Positron-Emission Tomography/methods, Lewy Body Disease/diagnostic imaging",

author = "Masdeu, {Joseph C.}",

note = "Publisher Copyright: {\textcopyright} 2019 Elsevier Inc.",

year = "2020",

month = feb,

doi = "10.1016/j.ncl.2019.08.003",

language = "English (US)",

volume = "38",

pages = "65--94",

journal = "Neurologic Clinics",

issn = "0733-8619",

publisher = "W.B. Saunders Ltd",

number = "1",

}

TY - JOUR

T1 - Neuroimaging of Diseases Causing Dementia

AU - Masdeu, Joseph C.

PY - 2020/2

Y1 - 2020/2

N2 - Neuroimaging provides a window on the biological events underlying dementia. Amyloid PET is positive in Alzheimer disease (AD) and some cases of diffuse Lewy body disease, but negative in the frontotemporal dementias (FTDs). Tau PET using the current tracers shows the greatest signal in AD and a lesser signal in FTD. Quantifying volume loss with MRI and measuring metabolism with fluorodeoxyglucose PET helps separate different causes of dementia and follow their progression. Brain inflammation can be assessed with PET. Some of these techniques, still investigational, are likely to find their clinical niche in the near future.

AB - Neuroimaging provides a window on the biological events underlying dementia. Amyloid PET is positive in Alzheimer disease (AD) and some cases of diffuse Lewy body disease, but negative in the frontotemporal dementias (FTDs). Tau PET using the current tracers shows the greatest signal in AD and a lesser signal in FTD. Quantifying volume loss with MRI and measuring metabolism with fluorodeoxyglucose PET helps separate different causes of dementia and follow their progression. Brain inflammation can be assessed with PET. Some of these techniques, still investigational, are likely to find their clinical niche in the near future.

KW - Alzheimer disease

KW - Amyloid β

KW - Neurodegeneration

KW - Neuroimaging

KW - PET

KW - Tau

KW - tau Proteins/metabolism

KW - Humans

KW - Magnetic Resonance Imaging/methods

KW - Disease Progression

KW - Dementia/diagnostic imaging

KW - Neuroimaging/methods

KW - Frontotemporal Dementia/diagnostic imaging

KW - Alzheimer Disease/diagnostic imaging

KW - Positron-Emission Tomography/methods

KW - Lewy Body Disease/diagnostic imaging

UR - http://www.scopus.com/inward/record.url?scp=85075210326&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85075210326&partnerID=8YFLogxK

U2 - 10.1016/j.ncl.2019.08.003

DO - 10.1016/j.ncl.2019.08.003

M3 - Review article

C2 - 31761062

AN - SCOPUS:85075210326

SN - 0733-8619

VL - 38

SP - 65

EP - 94

JO - Neurologic Clinics

JF - Neurologic Clinics

IS - 1

ER -

Neuroimaging of Diseases Causing Dementia

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this